ADENOSINE TRIPHOSPHATE

SynDRA canonical compound SYN0000763 — structure-anchored drug synonym record

Clinical phase	Phase 2
Approval status	Approved · Rx/OTC
Primary target(s)	ABCA1 \| ABCB1 \| ABCB11 \| ABCC2 \| ABCC8 \| ABCC9 \| ABCG1 \| ABL1 \| ABL2 \| ACSL1 \| ACSS1 \| ACSS2 \| ACVR1 \| ACVR1B \| ACVRL1 \| ADCY1 \| ADRBK1 \| ADRBK2 \| AFG3L2 \| AKT1 \| ALK \| AMHR2 \| APAF1 \| ARAF \| ASNA1 \| ASNS \| ASS1 \| CDK15 \| GPR17 \| ITPR1 \| NAE1 \| NT5C2 \| P2RY1 \| P2RY11 \| P2RY13 \| P2RY2 \| P2RY4 \| PRKAA1 \| RYR1 \| RYR2 \| RYR3 \| SLC25A4 \| TNK2 \| TRPM4 \| TRPM7
Mechanism of action	adenosine receptor agonist

All known targets

ATP
triphosphoric acid adenosine ester
adenosine triphosphate disodium hydrate
Adenosine 5'-triphosphoric acid
Adenylpyrophosphate
Triphosadenine
Triphosadenine (DCF)
Adenosine 5'-triphosphate(4-)
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
[[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid
3b2q
5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid
9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]
adenosine-triphosphate
Triphosphaden
Myotriphos
Triadenyl
Glucobasin
Adetol
Adynol
Atipi
Adephos
Adenosine-5'-(tetrahydrogen triphosphate)
Adenylpyrophosphoric acid
5'-Atp
adenosine-5'-triphosphoric acid
Triphosphoric acid adenosine ester
adenosine-5'-triphosphate
adenylpyrophosphate
8L70Q75FXE
CHEBI:15422
DTXCID302559
Chromium Adenosine Triphosphate
Magnesium Adenosine Triphosphate
CaATP
CrATP
ATP-MgCl2